Literature DB >> 20877452

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing. Test category: pharmacogenomic (treatment).

Daurice Grossniklaus1.   

Abstract

Warfarin is an oral anticoagulant that is widely prescribed to prevent thromboembolic events in persons at increased risk. The optimal dose is difficult to establish because it can vary 10-fold among individuals due to clinical and demographic factors. Testing for variants of the vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) genes has been proposed for use in guiding the initial dose of warfarin, thus achieving optimal dosing more quickly and with lower risk of bleeding.

Entities:  

Year:  2010        PMID： 20877452      PMCID： PMC2940214          DOI： 10.1371/currents.RRN1155

Source DB:  PubMed          Journal:  PLoS Curr        ISSN： 2157-3999


  15 in total

1.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

2.  Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients.

Authors:  Fumihiko Takeuchi; Mitsuo Kashida; Osamu Okazaki; Yuriko Tanaka; Shoji Fukuda; Toshitaka Kashima; Shigeru Hosaka; Michiaki Hiroe; Sosuke Kimura; Norihiro Kato
Journal:  Circ J       Date:  2010-03-26       Impact factor: 2.993

3.  Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

Authors:  Robert S Epstein; Thomas P Moyer; Ronald E Aubert; Dennis J O Kane; Fang Xia; Robert R Verbrugge; Brian F Gage; J Russell Teagarden
Journal:  J Am Coll Cardiol       Date:  2010-04-08       Impact factor: 24.094

4.  Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.

Authors:  Gwendolyn A McMillin; Roberta Melis; Andrew Wilson; Michael B Strong; Nathan A Wanner; Russell G Vinik; Christopher L Peters; Robert C Pendleton
Journal:  Ther Drug Monit       Date:  2010-06       Impact factor: 3.681

5.  Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

Authors:  Nita A Limdi; Mia Wadelius; Larisa Cavallari; Niclas Eriksson; Dana C Crawford; Ming-Ta M Lee; Chien-Hsiun Chen; Alison Motsinger-Reif; Hersh Sagreiya; Nianjun Liu; Alan H B Wu; Brian F Gage; Andrea Jorgensen; Munir Pirmohamed; Jae-Gook Shin; Guilherme Suarez-Kurtz; Stephen E Kimmel; Julie A Johnson; Teri E Klein; Michael J Wagner
Journal:  Blood       Date:  2010-03-04       Impact factor: 22.113

6.  Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing.

Authors:  Nitin Roper; Barry Storer; Robert Bona; Min Fang
Journal:  J Mol Diagn       Date:  2010-03-12       Impact factor: 5.568

7.  Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Authors:  N A Limdi; H Wiener; J A Goldstein; R T Acton; T M Beasley
Journal:  Blood Cells Mol Dis       Date:  2009-03-17       Impact factor: 3.039

Review 8.  A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.

Authors:  Monica R McClain; Glenn E Palomaki; Margaret Piper; James E Haddow
Journal:  Genet Med       Date:  2008-02       Impact factor: 8.822

9.  Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.

Authors:  David A Flockhart; Dennis O'Kane; Marc S Williams; Michael S Watson; David A Flockhart; Brian Gage; Roy Gandolfi; Richard King; Elaine Lyon; Robert Nussbaum; Dennis O'Kane; Kevin Schulman; David Veenstra; Marc S Williams; Michael S Watson
Journal:  Genet Med       Date:  2008-02       Impact factor: 8.822

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245
View more
  6 in total

1.  The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use.

Authors:  David M Haas; Amalia S Lehmann; Todd Skaar; Santosh Philips; Catherine L McCormick; Kyle Beagle; Scott J Hebbring; Jessica Dantzer; Lang Li; Jeesun Jung
Journal:  Am J Obstet Gynecol       Date:  2012-02-28       Impact factor: 8.661

2.  The impact of glucocorticoid polymorphisms on markers of neonatal respiratory disease after antenatal betamethasone administration.

Authors:  David M Haas; Jessica Dantzer; Amalia S Lehmann; Santosh Philips; Todd C Skaar; Catherine L McCormick; Scott J Hebbring; Jeesun Jung; Lang Li
Journal:  Am J Obstet Gynecol       Date:  2013-01-04       Impact factor: 8.661

Review 3.  Drug Interactions Affecting Oral Anticoagulant Use.

Authors:  Philip L Mar; Rakesh Gopinathannair; Brooke E Gengler; Mina K Chung; Arturo Perez; Jonathan Dukes; Michael D Ezekowitz; Dhanunjaya Lakkireddy; Gregory Y H Lip; Mike Miletello; Peter A Noseworthy; James Reiffel; James E Tisdale; Brian Olshansky
Journal:  Circ Arrhythm Electrophysiol       Date:  2022-05-27

Review 4.  Pharmacogenetics and individualizing drug treatment during pregnancy.

Authors:  David M Haas
Journal:  Pharmacogenomics       Date:  2014-01       Impact factor: 2.533

5.  Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?

Authors:  David M Haas; Mary DʼAlton
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

6.  Incidentalome from Genomic Sequencing: A Barrier to Personalized Medicine?

Authors:  Saumya Shekhar Jamuar; Jyn Ling Kuan; Maggie Brett; Zenia Tiang; Wilson Lek Wen Tan; Jiin Ying Lim; Wendy Kein Meng Liew; Asif Javed; Woei Kang Liew; Hai Yang Law; Ee Shien Tan; Angeline Lai; Ivy Ng; Yik Ying Teo; Byrappa Venkatesh; Bruno Reversade; Ene Choo Tan; Roger Foo
Journal:  EBioMedicine       Date:  2016-02-04       Impact factor: 8.143
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.